Asia's Innovation Horizon: Insiders Are Optimistic And Wary
This article was originally published in PharmAsia News
Executive SummarySINGAPORE - Multinationals are dropping substantial resources in R&D in Asia, but - excluding Japan - Asian countries have yet to create a significant new drug approval, and opinions differ on when strong INDs will begin to appear out of the region
You may also be interested in...
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).